Search

Your search keyword '"Russcher, Anne"' showing total 25 results
Start Over Author "Russcher, Anne"
25 results on '"Russcher, Anne"'

3. Highly Divergent SARS-CoV-2 Alpha Variant in Chronically Infected Immunocompromised Person

Author

Munnink, Bas B. Oude, Nijhuis, Roel H.T., Worp, Nathalie, Boter, Marjan, Weller, Babette, Verstrepen, Babs E., GeurtsvanKessel, Corine, Corsten, Maarten L., Russcher, Anne, and Koopmans, Marion

Subjects
Immunocompromised host -- Case studies, Health
Abstract

Persons with an immune deficiency can be infected with viral pathogens for a prolonged period. This occurrence has been reported for noroviruses (1) but also has been documented for SARS-CoV-2 [...]

Published
2022
Full Text
View/download PDF

4. Changing epidemiology of parvovirus B19 in the Netherlands since 1990, including its re-emergence after the COVID-19 pandemic

Author

Epi Infectieziekten, Infection & Immunity, Russcher, Anne, van Boven, Michiel, Benincà, Elisa, Verweij, E. J.T., Molenaar-de Backer, Marijke W.A., Zaaijer, Hans L., Vossen, Ann C.T.M., Kroes, Aloys C.M., Epi Infectieziekten, Infection & Immunity, Russcher, Anne, van Boven, Michiel, Benincà, Elisa, Verweij, E. J.T., Molenaar-de Backer, Marijke W.A., Zaaijer, Hans L., Vossen, Ann C.T.M., and Kroes, Aloys C.M.

Published
2024

8. Highly Divergent SARS-CoV-2 Alpha Variant in Chronically Infected Immunocompromised Person

Author

Oude Munnink, Bas B., Nijhuis, Roel H.T., Worp, Nathalie, Boter, Marjan, Weller, Babette, Verstrepen, Babs E., GeurtsvanKessel, Corine, Corsten, Maarten L., Russcher, Anne, Koopmans, Marion, Oude Munnink, Bas B., Nijhuis, Roel H.T., Worp, Nathalie, Boter, Marjan, Weller, Babette, Verstrepen, Babs E., GeurtsvanKessel, Corine, Corsten, Maarten L., Russcher, Anne, and Koopmans, Marion

Abstract

We detected a highly divergent SARS-CoV-2 Alpha variant in an immunocompromised person several months after the latest detection of the Alpha variant in the Netherlands. The patient was infected for 42 weeks despite several treatment regimens and disappearance of most clinical symptoms. We identified several potential immune escape mutations in the spike protein.

Published
2022

10. Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid and antibody tests up to 22 August 2020

Author

Van Walle, Ivo, Leitmeyer, Katrin, Broberg, Eeva K, Van Esbroeck, Marjan, Beuselinck, Kurt, Vermeersch, Pieter, Karagiannis, Christos, Mentis, Andreas, Lampropoulou, Stavroula, Erlund, Iris, Melin, Merit, Ekström, Nina, Vihervaara, Terhi, Gaymard, Alexandre, Frobert, Emilie, Escuret, Vanessa, Kurolt, Ivan-Christian, Fournier, Guillaume, Abdelrahman, Tamir, Nguyen, Trung, Klak, Adrian, Bos, Anne E, Russcher, Anne, van ’t Veen, Annemarie, Stemerding, Annette M, van Corteveen-Splinter, Annette, van Hees, Babette C, Wintermans, Bas B, Herpers, Bjorn L, Reusken, Chantal BEM, van der Donk, Christel FM, Oliveira dos Santos, Claudy, GeurtsvanKessel, Corine H, Timmerman, Cornelis P, Ong, David SY, Kaersenhout, Deborah J, van Lochem, Ellen, Geeraedts, Felix, Rijkers, Ger T, Berkhout, Hannke, Koeleman, Hans GM, van Loo, Inge HM, Rahamat-Langendoen, Janette, Murk, Jean-Luc, Tjhie, Jeroen HT, Kissing, Johan, Reimerink, Johan, Kerremans, Jos J, de Vries, Jutte JC, Heemstra, Karen A, Thai, Khoa TD, Jim, Kin Ki, Mulder, Leontine, van den Beld, Maaike JC, Batstra, Manou R, Konstantinovski, Maria M, Wegdam-Blans, Marjolijn CA, Hoogewerf, Martine, de Graaf, Melanie J, de Jong, Menno D., Heron, Michiel, van Rijn, Michiel, Heusinkveld, Moniek, Van Burgel, Nathalie, Savelkoul, Paul HM, den Reijer, Paul Martijn, Wever, Peter C, Croughs, Peter, Zonneveld, Rens, van Gyseghem, Sim, Thijsen, Steven FT, Stoof, Susanne P, Jurriaans, Suzanne, Debast, Sylvia B, Mank, Theo, Hira, Vishal, Michalski, Aleksander, Siewierska-Puchlerska, Anna, Gajda, Ewa, Paciorek, Jarosław, Pakieła, Marta, Kołakowska-Kulesza, Agnieszka, Pancer, Katarzyna, Nowakowska, Magdalena, Costa, Inês, Zé-Zé, Líbia, Guiomar, Raquel, Hammas, Berit, Öckinger, Johan Brynedal, Prosenc, Katarina, and Berginc, Nataša

Subjects
Infecções Respiratórias, medicine.medical_specialty, Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), diagnostic, specificity, Sensitivity and Specificity, Gastroenterology, Asymptomatic, Nucleic Acids, Virology, Internal medicine, medicine, Humans, media_common.cataloged_instance, European union, Pandemics, media_common, Infecções Sistémicas e Zoonoses, accuracy, biology, SARS-CoV-2, business.industry, Research, Public Health, Environmental and Occupational Health, COVID-19, sensitivity, Confidence interval, meta-analysis, Study heterogeneity, Meta-analysis, biology.protein, Nucleic acid, Antibody Tests, Antibody, medicine.symptom, business
Abstract

Background Reliable testing for SARS-CoV-2 is key for the management of the COVID-19 pandemic. Aim We estimate diagnostic accuracy for nucleic acid and antibody tests 5 months into the COVID-19 pandemic, and compare with manufacturer-reported accuracy. Methods We reviewed the clinical performance of SARS-CoV-2 nucleic acid and antibody tests based on 93,757 test results from 151 published studies and 20,205 new test results from 12 countries in the European Union and European Economic Area (EU/EEA). Results Pooling the results and considering only results with 95% confidence interval width ≤ 5%, we found four nucleic acid tests, including one point-of-care test and three antibody tests, with a clinical sensitivity ≥ 95% for at least one target population (hospitalised, mild or asymptomatic, or unknown). Nine nucleic acid tests and 25 antibody tests, 12 of them point-of-care tests, had a clinical specificity of ≥ 98%. Three antibody tests achieved both thresholds. Evidence for nucleic acid point-of-care tests remains scarce at present, and sensitivity varied substantially. Study heterogeneity was low for eight of 14 sensitivity and 68 of 84 specificity results with confidence interval width ≤ 5%, and lower for nucleic acid tests than antibody tests. Manufacturer-reported clinical performance was significantly higher than independently assessed in 11 of 32 and four of 34 cases, respectively, for sensitivity and specificity, indicating a need for improvement in this area. Conclusion Continuous monitoring of clinical performance within more clearly defined target populations is needed.

Published
2021

14. Evaluation of the Atellica® UAS 800: a new member of the automated urine sediment analyzer family.

Author

Aper, Stijn J. A., Gijzen, Karlijn, Luimstra, Jolien J., van der Valk, Johanna T. M. H., Russcher, Anne, Koçer, Rüya G., Liesting, Eline C., Jacobs, Leo H. J., Lentjes, Eef G. W. M., and Demir, Ayşe Y.

Subjects
CLINICAL biochemistry, CLINICAL medicine, CHEMICAL laboratories, SPECTROPHOTOMETRY, TRACE element analysis
Abstract

In 2017 the Atellica® UAS 800 urine sediment analyzer was introduced by Siemens Healthineers. We investigated its applicability in the standardization and automation of the laboratory urinalysis workflow, including the prediction of urine culture outcome and glomerular pathology. We evaluated the performance characteristics of the Atellica® UAS 800 and its correlation with the iQ200 (Beckman Coulter). In addition, we studied the agreement between Atellica® UAS 800 and CLINITEK Novus® and determined the predictive value of bacteria and leukocyte counts for urine culture outcome. Furthermore, we investigated the ability of Atellica® UAS 800 to identify pathological casts and dysmorphic erythrocytes in comparison to manual microscopy. Erythrocyte and leukocyte analyses indicated high intra- and inter-run precisions and good correlations with the iQ200. We found that the Atellica® UAS 800 detects bacteria with higher sensitivity than the iQ200. The Atellica® UAS 800 and CLINITEK Novus® showed a high degree of conformity. We determined seven combinations of clinical cut-off values of bacteria and leukocytes for predicting urine culture outcome with sensitivity, specificity, and negative predictive values of 95%, 52%, and 93%, respectively. Using the Atellica® UAS 800, hyaline casts, erythrocyte casts, leukocyte casts, and dysmorphic erythrocytes were correctly recognized in 76%, 22%, 2%, and 39% of the samples, respectively. The Atellica® UAS 800 is a robust, fast, and user-friendly analyzer, which accurately quantifies erythrocytes, leukocytes, bacteria and squamous epithelial cells, and may be utilized for predicting positive urine cultures. The detection of clinically important pathological casts and dysmorphic erythrocytes proved insufficient. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

15. Necrotising fasciitis as atypical presentation of infection with emerging Neisseria meningitidis serogroup W (MenW) clonal complex 11, the Netherlands, March 2017

Author

Russcher, Anne, Fanoy, Ewout, van Olden, Ger D J, Graafland, Antonie D, van der Ende, Arie, and Knol, Mirjam J

Subjects
Meningococcal Infections, Treatment Outcome, Debridement, Fever, Neisseria meningitidis, Serogroup W-135, Clindamycin, Sepsis, Humans, Penicillin G, Fasciitis, Necrotizing, Meningitis, Meningococcal, Serogroup, Anti-Bacterial Agents
Abstract

In March 2017, a patient with necrotising fasciitis caused by Neisseria meningitidis serogroup W (MenW) clonal complex 11 was diagnosed in the Netherlands. Unusual and severe presentations of MenW infections are common in the current European epidemic. In the Netherlands, the incidence of MenW infections increased 10-fold, from an average of 0.03 per 100,000 population in 2002-2014 to 0.29 in 2016. Awareness of atypical presentations enables timely adequate treatment and public health action.

Published
2018

23. Interlaboratory Collaboration for Optimized Screening for Urinary Tract Infection

Author

Russcher, Anne, Kusters, Elske, Wolterbeek, Ron, Kuijper, Ed J., Cobbaert, Christa M., and van der Beek, Martha T.

Abstract

ABSTRACTAs the majority of urine samples submitted for culture yields a negative result, rapid screening that accurately predicts culture outcome benefits clinicians by reducing the time to result and improves the efficiency of the microbiological laboratory. Automated urinalysis using the IRIS Diagnostics iQ200 Elite (iQ200) analyzer permits just such a fast and large-scale screening. We aimed to predict and thus to reduce negative cultures with a screening algorithm based on iQ200 urinalysis in a tertiary university hospital. In parallel, we evaluated the performance of the iQ200 screen compared to that of Gram stain for sample quality. We screened 1,442 samples submitted for bacterial culture using the iQ200 analyzer; of these samples, 357 (24.8%) had a positive culture result. We identified the absence of microorganisms in the iQ200 screen as the strongest solitary predictor for a negative culture, with a sensitivity of 90.5% (323/357). The algorithm was further improved by performing logistic regression on leukocyte counts, which gave a cutoff of 65 leukocytes/µl to obtain the desired sensitivity of >95% (95.2%; 95% confidence interval [CI], 92.5 to 97.0), a negative predictive value of 97.3% (95% CI, 95.7 to 98.3), and an anticipated culture workload reduction of 44% (95% CI, 41 to 46). Concordance between sample quality based on Gram stain and iQ200 screening was only 72%, which was probably a result of interobserver effect in evaluation of the Gram stain. In conclusion, in our setting, screening by iQ200 proved to be a safe and cost-effective means to provide faster culture results, and it has the added benefit of a more objective evaluation of sample quality.

Published
2015
Full Text
View/download PDF

24. Evaluation of the Atellica ® UAS 800: a new member of the automated urine sediment analyzer family.

Author

Aper SJA, Gijzen K, Luimstra JJ, van der Valk JTMH, Russcher A, Koçer RG, Liesting EC, Jacobs LHJ, Lentjes EGWM, and Demir AY

Subjects
Automation, Bacteria metabolism, Erythrocytes cytology, Humans, Leukocytes cytology, Logistic Models, ROC Curve, Sensitivity and Specificity, Urinalysis instrumentation
Abstract

Background: In 2017 the Atellica ® UAS 800 urine sediment analyzer was introduced by Siemens Healthineers. We investigated its applicability in the standardization and automation of the laboratory urinalysis workflow, including the prediction of urine culture outcome and glomerular pathology., Methods: We evaluated the performance characteristics of the Atellica ® UAS 800 and its correlation with the iQ200 (Beckman Coulter). In addition, we studied the agreement between Atellica ® UAS 800 and CLINITEK Novus ® and determined the predictive value of bacteria and leukocyte counts for urine culture outcome. Furthermore, we investigated the ability of Atellica ® UAS 800 to identify pathological casts and dysmorphic erythrocytes in comparison to manual microscopy., Results: Erythrocyte and leukocyte analyses indicated high intra- and inter-run precisions and good correlations with the iQ200. We found that the Atellica ® UAS 800 detects bacteria with higher sensitivity than the iQ200. The Atellica ® UAS 800 and CLINITEK Novus ® showed a high degree of conformity. We determined seven combinations of clinical cut-off values of bacteria and leukocytes for predicting urine culture outcome with sensitivity, specificity, and negative predictive values of 95%, 52%, and 93%, respectively. Using the Atellica ® UAS 800, hyaline casts, erythrocyte casts, leukocyte casts, and dysmorphic erythrocytes were correctly recognized in 76%, 22%, 2%, and 39% of the samples, respectively., Conclusions: The Atellica ® UAS 800 is a robust, fast, and user-friendly analyzer, which accurately quantifies erythrocytes, leukocytes, bacteria and squamous epithelial cells, and may be utilized for predicting positive urine cultures. The detection of clinically important pathological casts and dysmorphic erythrocytes proved insufficient.

Published
2021
Full Text
View/download PDF

25. [Legionella pneumonia after the use of CPAP equipment].

Author

Stolk JM, Russcher A, van Elzakker EP, and Schippers EF

Subjects
Antibodies, Bacterial, Community-Acquired Infections, Humans, Legionnaires' Disease diagnosis, Male, Middle Aged, Radiography, Thoracic, Serotyping, Sputum microbiology, Continuous Positive Airway Pressure, Equipment Contamination, Legionella pneumophila isolation & purification, Legionnaires' Disease etiology
Abstract

Continuous positive airway pressure (CPAP) equipment can be colonised by Legionellae and might cause Legionella pneumonia in the user. However, there is no reported case of Legionella pneumonia related to CPAP equipment in which an identical Legionella was found in both the patient and the CPAP equipment. A 51-year-old man came to the Emergency Department with fever, confusion and dyspnoea that had been present for 3 days. His medical history included obstructive sleep apnoea, for which he had been using CPAP therapy at home for 10 weeks. The CPAP equipment showed signs of poor maintenance. Chest X-ray revealed a pulmonary consolidation. Laboratory investigation resulted in a positive urine antigen test for Legionella. Water from the CPAP equipment and sputum from the patient revealed Legionella pneumophila. Serotyping and sequence-based typing showed an identical L. pneumophila serotype 1 ST37. It is important to be aware that CPAP equipment can be colonised with Legionellae and might cause Legionella pneumonia. It is therefore necessary to ask about CPAP therapy in a patient with community-acquired pneumonia.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results